LLY
785.76
-1.21%↓
JNJ
152.76
+0.26%↑
ABBV
186.41
-0.43%↓
NVO
68.78
+2.32%↑
UNH
307.81
+1.17%↑
LLY
785.76
-1.21%↓
JNJ
152.76
+0.26%↑
ABBV
186.41
-0.43%↓
NVO
68.78
+2.32%↑
UNH
307.81
+1.17%↑
LLY
785.76
-1.21%↓
JNJ
152.76
+0.26%↑
ABBV
186.41
-0.43%↓
NVO
68.78
+2.32%↑
UNH
307.81
+1.17%↑
LLY
785.76
-1.21%↓
JNJ
152.76
+0.26%↑
ABBV
186.41
-0.43%↓
NVO
68.78
+2.32%↑
UNH
307.81
+1.17%↑
LLY
785.76
-1.21%↓
JNJ
152.76
+0.26%↑
ABBV
186.41
-0.43%↓
NVO
68.78
+2.32%↑
UNH
307.81
+1.17%↑
24h
Praegune
Min
232.55
Max
260.68
Sissetulek | 153M 1.3M |
---|---|
Müük | -11M 1.1B |
Kasumimarginaal | 0.114 |
Soovitused | Tugev "osta" hinnang |
---|---|
12 kuu keskmine prognoos | +31.16% upside |
Järgmine tulemuste avaldamine | 6. aug 2025 |
---|
Turukapital | 22B |
---|---|
Eelmine avamishind | 250.2 |
Eelmine sulgemishind | 244.17 |
By Acuity
50%
50%
154 / 380 Pingereas Healthcare
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
12. mai 2025, 02:16 UTC
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs
DJ
Loe
29. jaan 2025, 15:59 UTC
ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene
DJ
Loe
27. nov 2024, 15:22 UTC
BeiGene Shares Up on EU Approval for Gastric, Esophageal Cancer Treatment
DJ
Loe
21. nov 2024, 14:45 UTC
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
DJ
Loe
22. okt 2024, 18:39 UTC
Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment
DJ
Loe
7. mai 2025, 10:07 UTC
BeiGene Maintains 2025 Expense Guidance of $4.1B to $4.4B >ONC
DJ
Loe
7. mai 2025, 10:06 UTC
BeiGene Backs 2025 Rev $4.9B-$5.3B >ONC
DJ
Loe
7. mai 2025, 10:05 UTC
BeiGene 1Q Net $1.27M >ONC
DJ
Loe
7. mai 2025, 10:04 UTC
BeiGene Says to Rename Company to BeOne Medicines >ONC
DJ
Loe
7. mai 2025, 10:02 UTC
BeiGene 1Q EPS $0.00 >ONC
DJ
Loe
7. mai 2025, 10:02 UTC
BeiGene 1Q Rev Increased 49% >ONC
DJ
Loe
7. mai 2025, 10:00 UTC
BeiGene 1Q Rev $1.12B >ONC
DJ
Loe
27. veebr 2025, 11:07 UTC
BeiGene Sees 2025 Rev $4.9B-$5.3B >ONC
DJ
Loe
27. veebr 2025, 11:06 UTC
BeiGene 4Q Global BRUKINSA Rev of $828M >ONC
DJ
Loe
27. veebr 2025, 11:06 UTC
BeiGene 4Q Loss/Shr 11c >ONC
DJ
Loe
27. veebr 2025, 11:06 UTC
BeiGene 4Q Rev $1.13B >ONC
DJ
Loe
12. nov 2024, 11:01 UTC
BeiGene 3Q Loss/Shr 9c >BGNE
DJ
Loe
12. nov 2024, 11:01 UTC
BeiGene 3Q Rev $1B >BGNE
DJ
Loe
7. aug 2024, 10:05 UTC
BeiGene 2Q Loss/Shr $1.15 >BGNE
DJ
Loe
7. aug 2024, 10:04 UTC
BeiGene 2Q Rev $929M >BGNE
DJ
Loe
Hinnamuutus
By TipRanks
12 kuu keskmine prognoos
Keskmine 333.78 USD 31.16%
Kõrge 359.47 USD
Madal 300 USD
Põhineb 8 Wall Streeti analüütiku instrumendi BeOne Medicines Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.
By TipRanks
Tugev "osta" hinnang
8 ratings
7
Osta
1
Hoia
0
Müü
Põhineb 8 analüütiku instrumendi BeOne Medicines Ltd ADR aktsia reitingul - viimase 3 kuu andmed.
By Acuity
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Keskmine
Müügi- ja halduskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Ärikasum
$